Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials-Reference-Cited by-同舟云学术

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

Published:2015-01-14 Issue:2 Volume:29 Page:167-174
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Raffi François,Rachlis Anita,Brinson Cynthia,Arasteh Keikawus,Górgolas Miguel,Brennan Clare,Pappa Keith,Almond Steve,Granier Catherine,Nichols W. Garrett,Cuffe Robert Liam,Jr Joseph Eron,Walmsley Sharon

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference9 articles.

1. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy.;Branas;Am J Med,2008

2. A prospective, 96-week study of the impact of Trizivir, Combivirnelfinavir and lamivudinestavudinenelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.;Kumar;HIV Med,2006

3. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B andor C virus coinfection.;Rockstroh;HIV Med,2012

4. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study.;Raffi;Lancet,2013

5. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.;Walmsley;N Engl J Med,2013

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria;PLOS ONE;2023-05-17

2. Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis;Clinical Infectious Diseases;2023-03-28

3. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases;Frontiers in Medicine;2021-10-04

4. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs;Viruses;2021-01-29

5. Demographic and clinical factors associated with immune reconstitution in HIV/HBV co‐infected and HIV mono‐infected patients: a retrospective cohort study;HIV Medicine;2020-12